ATLASSummit Therapeutics (SMMT) Q3 2026 earnings results
Summit Therapeutics (SMMT) reported EPS of -$0.31 against an analyst estimate of -$0.28: a miss of $0.03 (10.7%). The quarter ended Sep 30, 2026; the company reported on Monday, November 2, 2026.
Status: Confirmed · 06:45 ET, Nov 2 · Source: EODHD (calendar and fundamentals, cross-checked)
Notify me when Summit Therapeutics reports
Track SMMT free Add Summit Therapeutics to a free ATLAS watchlist.
SMMT Q3 2026 results at a glance
| EPS reported | -$0.31 |
|---|---|
| EPS estimate | -$0.28 |
| Surprise | Miss · -$0.03 (-10.7%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 2, 2026 |
| Status | Confirmed · 06:45 ET, Nov 2 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Summit Therapeutics’s Q3 2026, a calendar-year company.
Summit Therapeutics EPS surprise history: last 4 quarters
Summit Therapeutics beat the EPS estimate in 1 of its last 4 reports, with an average surprise of -499.1%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 2, 2026 | -$0.28 | -$0.31 | -10.7% | Miss | – |
| Jul 23, 2026 | -$0.21 | -$0.21 | 0.0% | In line | -7.3% |
| Apr 30, 2026 | -$0.21 | -$0.18 | +14.3% | Beat | -22.6% |
| Feb 23, 2026 | -$0.01 | -$0.21 | -2,000.0% | Miss | +1.1% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
SMMT stock reaction to the report
The price reaction will be added after the Nov 3, 2026 close.
This section appears once a post-report closing price exists and updates with every new close.
Next SMMT earnings report
Summit Therapeutics has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the SMMT earnings calendar.
ATLAS fair value and signal for SMMT
| Last price | $14.80 (-7.7%) |
|---|---|
| Chance of a higher close in 1 month | 47% (normal range $12.87–$16.49) |
These are model outputs from the same valuation and calibrated model as the Summit Therapeutics stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Summit Therapeutics Q3 2026 earnings: frequently asked questions
Did Summit Therapeutics beat earnings estimates for Q3 2026?
Summit Therapeutics reported EPS of -$0.31 against an analyst estimate of -$0.28: a miss of $0.03 (10.7%).
When did Summit Therapeutics report Q3 2026 results?
Summit Therapeutics reported on Monday, November 2, 2026, for the quarter ended Wednesday, September 30, 2026.
How often does SMMT beat EPS estimates?
In its last 4 reports with a recorded result, Summit Therapeutics beat the EPS estimate 1 times; the average surprise was -499.1%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer